Oramed Pharmaceuticals (NASDAQ:ORMP) COO Sells $135,300.00 in Stock

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) COO Joshua Hexter sold 30,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total value of $135,300.00. Following the sale, the chief operating officer owned 1,328,130 shares in the company, valued at $5,989,866.30. This trade represents a 2.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oramed Pharmaceuticals Stock Performance

Oramed Pharmaceuticals stock opened at $4.49 on Monday. The firm has a market capitalization of $186.78 million, a P/E ratio of 1.09 and a beta of 1.29. The stock has a fifty day moving average price of $4.64 and a 200 day moving average price of $4.20. Oramed Pharmaceuticals Inc. has a 52 week low of $2.09 and a 52 week high of $5.47.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.52). As a group, equities analysts predict that Oramed Pharmaceuticals Inc. will post 1.47 EPS for the current year.

Analyst Ratings Changes

ORMP has been the subject of a number of research reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Oramed Pharmaceuticals in a research report on Tuesday, September 8th. Wall Street Zen raised Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Institutional Trading of Oramed Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Ritholtz Wealth Management purchased a new position in Oramed Pharmaceuticals in the first quarter valued at about $529,000. SB Capital Management Inc acquired a new stake in shares of Oramed Pharmaceuticals in the fourth quarter valued at about $5,415,000. Redwood Family Wealth LLC acquired a new stake in shares of Oramed Pharmaceuticals in the fourth quarter valued at about $66,000. Engineers Gate Manager LP purchased a new stake in shares of Oramed Pharmaceuticals during the 2nd quarter valued at about $61,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Oramed Pharmaceuticals during the 2nd quarter valued at about $381,000. 12.73% of the stock is owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a biopharmaceutical company focused on developing oral delivery technologies for biologic drugs, including proteins and peptides that are traditionally administered by injection. Its technology is designed to protect these therapies as they pass through the gastrointestinal tract and facilitate absorption into the bloodstream.

The company’s lead programs have included ORMD-0801, an oral insulin candidate developed for the treatment of diabetes, and oral formulations of other peptide-based therapies.